Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm.

Trial Profile

A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myeloproliferative disorders; Splenomegaly; Venous thrombosis
  • Focus Therapeutic Use
  • Acronyms SVT-RUXO
  • Most Recent Events

    • 08 Dec 2015 Long term follow-up results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 23 Apr 2015 Status changed from recruiting to active, no longer recruiting, according to the abstract presented at the 56th annual meeting and exposition of the american society of hematology
    • 09 Dec 2014 interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top